Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Running, not enrolling · Phase 3

Conditions studied: Relapsing-remitting Multiple Sclerosis (RRMS)

In brief

The Main objectives of the study are to demonstrate pharmacokinetic (PK) similarity between ABP 692 and ocrelizumab (US), as well as between ABP 692 and ocrelizumab (EU).

Key facts

Study ID

NCT06700343

Run by

Amgen

People needed

152

Starts

2025-01-13

Expected to finish

2027-10-04

Last updated by the study team

2026-07-27

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of RRMS in accordance with the revised McDonald Criteria 2017 (Thompson et al, 2018).
• Expanded Disability Status Scale score at screening ≥ 0 and ≤ 5.5 inclusive.
• Evidence of recent MS activity as defined by the study protocol.
• Neurologically stable subject, with no relapse for ≤ 28 days before randomization.

You may not qualify if…

• Diagnosis of primary progressive or with secondary progressive MS (Thompson et al, 2018).
• Multiple sclerosis disease duration of ≥ 10 years in Participants with Expanded Disability Status Scale (EDSS) score of ≤ 2.5 at screening.
• Any contraindications to study procedures or medications as outlined in the study protocol.
• Any prohibited medication as defined in the study protocol.
• Any significant concomitant disease that may require chronic treatment with systemic corticosteroids and/or systemic immunosuppressants during the study.
• Current or history of any significant medical conditions as described in the study protocol.
• Any abnormal laboratory blood values as defined in the study protocol.

Where it is running

• Clinical Endpoints, LLC — Scottsdale, Arizona, United States
• Profound Research - Neurology Center of Southern California — Carlsbad, California, United States
• Mountain Neurological Research Center — Basalt, Colorado, United States
• Advanced Neurosciences Research, Llc — Fort Collins, Colorado, United States
• Hasbani Neurology — New Haven, Connecticut, United States
• Neurology Offices of South Florida — Boca Raton, Florida, United States
• Aqualane Clinical Research — Naples, Florida, United States
• Emerald Coast Neurology/Synergy Clinical Research — Pensacola, Florida, United States
• Knight Neurology — Rockledge, Florida, United States
• Premiere Research Institute Palm Beach — West Palm Beach, Florida, United States
• Hawaii Pacific Neuroscience — Honolulu, Hawaii, United States
• Rush University Medical Center, Rush University Cancer Center — Chicago, Illinois, United States
• University of Kansas Medical Center — Kansas City, Kansas, United States
• Henry Ford Health — Detroit, Michigan, United States
• Michigan Institute For Neurological Disorders (Glendale Neurological Associates) - Farmington Hills — Farmington, Michigan, United States
• JFK Medical Center — Edison, New Jersey, United States
• Hackensack Meridian Health — Paramus, New Jersey, United States
• University of NM/Mind Imaging center — Albuquerque, New Mexico, United States
• Triad Neurological Associates — Winston-Salem, North Carolina, United States
• Singlepoint Healthcare Opco, LLC — Columbus, Ohio, United States
• NDx Clinical Research, Inc — Dayton, Ohio, United States
• Premier Neurology, PC — Greenville, South Carolina, United States
• Hope Neurology — Knoxville, Tennessee, United States
• Vanderbilt University Medical Center (VUMC) — Nashville, Tennessee, United States
• University of South Alabama — Mobile, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.